"Transfer" Astraika prevented the former executive from entering GSK and temporarily won

Source: Siqi Club/Four Leaf Grass

"Critical moment", Astraikon successfully prevented the former executive from entering GSK.

On September 1st, the former executive of Astraikon, Chris Sheldon, should have begun to work in Grammot (GSK). The paper temporary ban was prevented.

According to the British "Financial Times" and "Bloomberg News", on Wednesday, Astraika applied for an emergency ban to the London Higher Court to prevent Sheldon from entering Grandulos the next day. It is reported that the case will be tried in October.

The incident has to go back to July this year, and Astraco sued the company's former investor relationship vice president Chris Sheldon for the first time, saying that he joined the Grandulsk before February that violated the competition that was valid for 6 months. Restricted agreement and tried to prevent them from joining GlaxoSmiths to share key therapeutic information.

If you join Grandulosk, Chris Schelton will serve as a senior vice president of the company's business portfolio investment, and it originally planned to join the post on September 1.

"Although we are disappointed with this temporary ban, we still believe that Dr. Sheldon's position is firm and believe that he will be able to start the new role of Grammot after the main hearing in October." Gelai A spokesman for Lan Susk said through an email, "Regardless of the result of the next hearing, we are looking forward to Dr. Sheldon's joining in the next few months, and the professional he will bring to GlaxoSmithK Knowledge."

Astrick told a number of media that Sheldon signed a competitive restriction agreement in 2021 and thus obtained more than 644,000 pounds ($ 774,090) of Astraikon. According to Astraikon, Schelton shall not enter the field of respiratory, tumors and Covid-19 within half a year after leaving Astraon.

However, Shelton denied any illegal act and stated that he had revealed to Asley in April that he would replace the company's plan.

In fact, disputes between Astraikon and GlaxoSmith on the restrictions on employee competition restrictions, this case is not the first case.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -